Get started
Author

Stephan Bildat

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
2017 · for the SAKK and the German CML Study Group, R Hehlmann, et al. · Leukemia · 341
PDF
Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer
2001 · Joachim von Pawel, Ulrich Gatzemeier, et al. · Journal of Clinical Oncology · 234
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
2020 · Rüdiger Hehlmann, Astghik Voskanyan, et al. · Leukemia · 91
PDF
Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results
1999 · Georgios Stamatis, Wilfried Eberhardt, et al. · The Annals of Thoracic Surgery · 91
PDF
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)
2013 · Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, et al. · Lung Cancer · 25
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry
2020 · Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, et al. · International Journal of Cancer · 22
PDF
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
2018 · Christian Michel, Andreas Burchert, et al. · Haematologica · 22
PDF
Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb):a pilot phase I/II trial
2002 · C. Pöttgen, W. Eberhardt, et al. · Annals of Oncology · 22
PDF
Lung cancer: Combined modality therapy in NSCLC
2000 · Wilfried Eberhardt, Stephan Bildat, et al. · Annals of Oncology · 16
Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy (CT) in patients with metastatic non-small cell lung cancer (NSCLC)
1999 · S. Bildat, U. Gatzemeier, et al. · European Journal of Cancer · 10
Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase
2017 · Rüdiger Hehlmann, Michael Lauseker, et al. · Blood · 8
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
2020 · Rüdiger Hehlmann, Astghik Voskanyan, et al. · Leukemia · 6
PDF
Preoperative treatment strategies in stage III non-small cell lung cancer
2001 · Wilfried Eberhardt, Stephan Bildat, et al. · Lung Cancer · 5
P-604 Multicenter German/French phase-II trial of induction-CTx followed by concurrent CTx/RTx +/- surgery (S) in locally far advanced inoperable non-small-cell lung cancer (NSCLC) stages IIIA(N2) and IIIB - preliminary results of toxicity and efficacy including a newer induction-CTx regimen
2003 · Thomas Gauler, Wilfried Ernst-Erich Eberhardt, et al. · Lung Cancer · 4
Untitled
2000 · Wilfried Eberhardt, Stephan Bildat, et al. · Annals of Oncology · 4
O-213 Operable stage IIIA NSCLC: prospectively randomized multicenter German trial of surgery and postoperative radiotherapy versus “trimodality treatment” — analysis of surgical results and toxicity
2003 · Wilfried Ernst Erich Eberhardt, Sönke Korfee, et al. · Lung Cancer · 3
“Minimal N2-disease” (operable) stage IIIa non-small cell lung cancer: Prospectively randomized multicenter German phase-III-trial of surgery (S) followed by adjuvant radiotherapy (RTx) versus “Trimodality treatment” — Early results of feasibility and toxicity in this setting
2000 · W Eberhardt, S Korfee, et al. · Lung Cancer · 3
Assessment of Imatinib 400mg as First Line Treatment of Chronic Myeloid Leukemia: 10-year Survival Results of the Randomized Cml Study Iv
2017 · Rüdiger Hehlmann, Mariele Goebeler, et al. · Kölner Universitäts PublikationsServer (Universität zu Köln) · 2
Long-term survival (S) of induction chemotherapy (CTx) with three cycles cisplatin (cis)/paclitaxel (pac) followed by concurrent (cc) chemoradiation (CTx/RTx) cis/etoposide (eto) and 45 Gy (1.5 Gy bid) plus surgery (SURG): Phase II results (CISTAXOL).
2011 · W. E. E. Eberhardt, T. C. Gauler, et al. · Journal of Clinical Oncology · 2
The expression of oxytocin receptor (OXTR) in metastatic pancreatic neuroendocrine tumors (PNETs)
2020 · Darko Katalinic, Stephan Bildat, et al. · Endocrine Abstracts
The expression of HER2-gene polymorphisms -1985G>T and P1170A C>G and their association with the risk of development of lung adenocarcinoma
2019 · I. Aleric, D. Katalinic, et al. · Annals of Oncology
PDF
Down-regulation of the Ataxia Telangiectasia Mutated Gene (ATM) is associated with increased metastatic potential and decreased overal survival in patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
2019 · Darko Katalinic, Ivan Aleric, et al. · Endocrine Abstracts
Gene mutation analysis and overal survival among the patints with neuroendocrine tumors of the lung and gastroenteropancreatic neuroendocrine tumors
2018 · Darko Katalinic, Ivan Aleric, et al. · Endocrine Abstracts
6608 POSTER An expanded access clinical program of erlotinib in patients (pts) with advanced stage IIIb/ IV non-small-cell lung cancer (NSCLC) – an update of a single institution experience
2007 · M. Tewes, T. Gauler, et al. · European Journal of Cancer Supplements
PET-CT for Patients (pts) Selection within a Multimodality Treatment Protocol (CTx + CTx/RTx ± S) in Pts with Locally Advanced (LAD) Non-Small Cell Lung Cancer (NSCLC)(Inoperable Stage IIIA/Selected IIIB)
2005 · M. Stuschke, C. Poettgen, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
Works count: 32
Citation count: 911
H-index: 10
I10-index: 10
Year
Topic
Type